Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023

Abstract
No abstract available
Funding Information
  • AstraZeneca Pharmaceuticals LP
  • Department of Veterans Affairs (through support for the National Post-Traumatic Stress Disorder Center) (R01; MH 65552)
  • AstraZeneca Pharmaceuticals LP
  • Pfizer Global Research and Development
  • GlaxoSmithKline